SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma - Quaterly Results

15 May 2024 Evaluate
The revenue zoomed 14.99% to Rs. 21526.87 millions for the quarter ended March 2024 as compared to Rs. 18721.22 millions during the corresponding quarter last year.Handsome Net Profit growth of 61.63% reported above the corresponding previous quarter figure of Rs. 4541.70 millions to Rs. 2809.88 millions.Operating profit for the quarter ended March 2024 rose to 6311.87 millions as compared to 4236.17 millions of corresponding quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 21526.87 18721.22 14.99 92648.09 81271.53 14.00 92648.09 81271.53 14.00
Other Income 838.54 424.55 97.51 2666.38 1627.83 63.80 2666.38 1627.83 63.80
PBIDT 6311.87 4236.17 49.00 25917.44 18601.65 39.33 25917.44 18601.65 39.33
Interest 40.34 8.85 355.82 145.70 277.48 -47.49 145.70 277.48 -47.49
PBDT 6271.53 4227.32 48.36 25771.74 18324.17 40.64 25771.74 18324.17 40.64
Depreciation 822.93 672.98 22.28 3176.06 2695.80 17.82 3176.06 2695.80 17.82
PBT 5448.60 3554.34 53.29 22595.68 15628.37 44.58 22595.68 15628.37 44.58
TAX 906.90 744.46 21.82 4361.57 3145.79 38.65 4361.57 3145.79 38.65
Deferred Tax -199.64 -64.48 209.62 195.98 229.43 -14.58 195.98 229.43 -14.58
PAT 4541.70 2809.88 61.63 18234.11 12482.58 46.08 18234.11 12482.58 46.08
Equity 400.59 400.59 0.00 400.59 400.59 0.00 400.59 400.59 0.00
PBIDTM(%) 29.32 22.63 29.58 27.97 22.89 22.22 27.97 22.89 22.22

Mankind Pharma Share Price

2286.00 -5.85 (-0.26%)
24-Apr-2026 12:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.40
Dr. Reddys Lab 1321.20
Cipla 1287.75
Zydus Lifesciences 930.25
Lupin 2270.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×